Premium
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
Author(s) -
Aoki Takahiro,
Hino Moeko,
Koh Katsuyoshi,
Kyushiki Masashi,
Kishimoto Hiroshi,
Arakawa Yuki,
Hanada Ryoji,
Kawashima Hiroshi,
Kurihara Jun,
Shimojo Naoki,
Motohashi Shinichiro
Publication year - 2016
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26018
Subject(s) - medicine , rhabdomyosarcoma , medulloblastoma , hepatoblastoma , neuroblastoma , wilms' tumor , cancer research , pathology , cd8 , immunohistochemistry , pd l1 , cancer , sarcoma , immunotherapy , antigen , immunology , biology , cell culture , genetics
Programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD‐L1 expression and tumor‐infiltrating CD8 + T cells in formalin‐fixed, paraffin‐embedded tumor specimens from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor, rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor. One rhabdomyosarcoma with the shortest survival exhibited membranous PD‐L1 expression and germinoma contained abundant tumor‐infiltrating CD8 + T cells and PD‐L1‐positive macrophages. The PD‐1/PD‐L1 pathway tended to be inactive in pediatric cancers.